The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a huge mover today! About 438,581 shares traded hands. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has declined 44.78% since April 4, 2016 and is downtrending. It has underperformed by 45.88% the S&P500.
The move comes after 8 months positive chart setup for the $1.23B company. It was reported on Nov, 4 by Barchart.com. We have $50.03 PT which if reached, will make NASDAQ:PCRX worth $651.90 million more.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage
Out of 10 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 70% are positive. Pacira Pharmaceuticals has been the topic of 20 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Mizuho maintained the shares of PCRX in a report on Thursday, November 3 with “Buy” rating. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Buy” rating given on Tuesday, May 3 by Mizuho. The firm has “Buy” rating by Bank of America given on Friday, January 29. The firm has “Outperform” rating by Wedbush given on Wednesday, October 19. On Tuesday, April 19 the stock rating was initiated by Mizuho with “Buy”. On Friday, October 7 the stock rating was reinitiated by Brean Capital with “Hold”. Nomura initiated the shares of PCRX in a report on Tuesday, September 29 with “Buy” rating. On Thursday, August 20 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Buy” rating by Brean Capital given on Friday, February 26. Jefferies maintained the shares of PCRX in a report on Monday, September 26 with “Buy” rating.
According to Zacks Investment Research, “Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.39, from 0.95 in 2016Q1. The ratio increased, as 41 funds sold all Pacira Pharmaceuticals Inc shares owned while 39 reduced positions. 36 funds bought stakes while 71 increased positions. They now own 39.74 million shares or 7.79% less from 43.10 million shares in 2016Q1.
Elk Creek Prns Ltd Liability holds 1.04% or 434,699 shares in its portfolio. Amer Group Inc holds 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 20,979 shares. Barclays Public Limited Com has 0% invested in the company for 23 shares. Arcadia Inv Mi reported 633 shares or 0.01% of all its holdings. Price T Rowe Associate Md accumulated 4.43 million shares or 0.03% of the stock. Moreover, Stephens Ar has 0.04% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 23,838 shares. Livingston Group Inc Asset Management Company (Operating As Southport Cap Management) last reported 100 shares in the company. Raymond James And Associate owns 14,025 shares or 0% of their US portfolio. The New York-based Tower Rech Cap Ltd Liability Corp (Trc) has invested 0.02% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Kingdon Mgmt Limited Liability Co holds 0.39% or 211,500 shares in its portfolio. Springbok Mngmt Ltd Company accumulated 1,144 shares or 0.01% of the stock. Schwab Charles Investment holds 0.01% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 122,428 shares. Loomis Sayles & Limited Partnership last reported 0% of its portfolio in the stock. National Bank & Trust Of New York Mellon holds 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 182,835 shares. Jpmorgan Chase & Com accumulated 0% or 94,024 shares.
Insider Transactions: Since June 6, 2016, the stock had 0 insider purchases, and 7 insider sales for $2.03 million net activity. STACK DAVID M sold 15,000 shares worth $679,800. 900 shares were sold by Kronenfeld Mark A., worth $42,255. $46,950 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were sold by Brege Laura. HASTINGS PAUL J also sold $53,335 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on Monday, June 6. $44,706 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by Riker Lauren Bullaro on Monday, June 6. 25,000 shares were sold by Scibetta James S, worth $1.13M. The insider Williams Kristen Marie sold 600 shares worth $28,319.
More news for Pacira Pharmaceuticals Inc (NASDAQ:PCRX) were recently published by: Fool.com, which released: “Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today” on August 04, 2016. Fool.com‘s article titled: “Pacira Pharmaceuticals Inc.’s Double-Digit Drop Explained” and published on May 02, 2016 is yet another important article.
PCRX Company Profile
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a specialty pharmaceutical company. The Firm is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The Company’s primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company makes for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.